Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

(2022) Luigi Francesco Iannone et al.   CNS DRUGS

Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine

(2022) Luigi Francesco Iannone et al.   EUROPEAN JOURNAL OF NEUROLOGY

059  Switching CGRP monoclonal antibodies for chronic migraine: real-world outcomes of 37 episodes

(2022) Mark Weatherall et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions

(2022) Linda Al-Hassany et al.   LANCET NEUROLOGY

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

(2022) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy : The multicenter prospective cohort GARLIT study

(2022) Fabrizio Vernieri et al.   EUROPEAN JOURNAL OF NEUROLOGY

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

(2022) Roberto De Icco et al.   JOURNAL OF HEADACHE AND PAIN

Early outcomes of migraine after erenumab discontinuation: data from a real-life setting

(2021) Eleonora De Matteis et al.   NEUROLOGICAL SCIENCES

Migraine therapeutics differentially modulate the CGRP pathway

(2021) Minoti Bhakta et al.   CEPHALALGIA

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study

(2021) Andreas R Gantenbein et al.   CEPHALALGIA

Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series

(2021) Ignacio Patier Ruiz et al.   EUROPEAN NEUROLOGY

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

(2021) Jessica Ailani et al.   HEADACHE

Diagnosis and management of migraine in ten steps

(2021) Anna K. Eigenbrodt et al.   Nature Reviews Neurology

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

(2021) Theodoros Mavridis et al.   Pharmaceuticals

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

(2021) Bianca Raffaelli et al.   CEPHALALGIA

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study

(2021) Lucas Hendrik Overeem et al.   CEPHALALGIA

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study

(2021) Alicia Alpuente et al.   JOURNAL OF HEADACHE AND PAIN

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

(2021) Fabrizio Vernieri et al.   JOURNAL OF HEADACHE AND PAIN

European headache federation consensus on the definition of resistant and refractory migraine

(2020) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class

(2019) Christian Ziegeler et al.   HEADACHE

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis

(2013) Kristian Thorlund et al.   CEPHALALGIA

The Importance of Placebo in Headache Research

(2008) H-C Diener et al.   CEPHALALGIA